Estimating the health utility of treatment in adults with growth hormone deficiency

Journal of Outcomes Research

Volumn 7, Issue 1-12, 2003, Pages 1-12

  Dixon, Simon ^a   McEwan, Phil ^b   Currie, Craig J ^b,c  

^a Cardiff Research Consortium Limited   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c HEALTH ECONOMICS AND OUTCOMES RESEARCH LTD   (United Kingdom)

Author keywords

AGHDA; Growth hormone deficiency; Individual item response model

Indexed keywords

HUMAN GROWTH HORMONE;

ALGORITHM; ARTICLE; COHORT ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFECT; GROWTH HORMONE DEFICIENCY; HEALTH CARE UTILIZATION; HORMONAL THERAPY; HUMAN; OUTCOMES RESEARCH; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RISK ASSESSMENT; SCORING SYSTEM; SOCIAL ISOLATION; WELLBEING;

EID: 0042235054     PISSN: 1369698X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. McGauley GA. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Growth Hormone and IGF Research 2000; (Suppl. B): S63-S68.
2. Gibney J, Wallance T, Spinks L et al. the effects of 10 years of recombinant human growth hormone (GH) in adult GH deficient patients. Journal of Clinical Endocrinology and Metabolism 1999; 84: 2596-2602.
3. McGauley GA. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Padiatrica Scandinavica 1989; (Suppl. 356): 70-72.
4. Wallymahmed ME, Foy P, Shaw D et al Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years. Clinical Endocrinology 1997; 47: 439-446.
5. Wiren L, Bengtsson BA, Johannsson G. Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clinical Endocrinology 1998; 48: 613-620.
6. Mardh G, Lundin K, Borg G, Jonsson B, Lindberg A. Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined data from 12 European placebo-controlled clinical trials. Endocrinology and Metabolism 1994; 1 (Suppl. A): 43-49.
7. Rosen T, Wiren L, Wilhelmsen L et al. Decreased psychological well-being in adults with growth hormone deficiency. Clinical Endocrinology 1994; 40: 111-116.
8. Holmes SJ, Shalet SM. Characteristics of adults who wish to enter a trail of growth hormone replacement. Clinical Endocrinology 1995; 42: 613-618.
9. Holmes SJ, Shalet SM. Factors influencing the desire for long-term growth hormone replacement in adults. Clinical Endocrinology 1995; 43: 151-157.
10. Baum H, Katznelson L, Sherman JC. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult onset GH deficiency. Journal of Clinical Endocrinology and Metabolism 1998; 83: 3184-3189
11. Cuneo RC, Judd S, Wallace J et al. The Australian multicenter trial of growth hormone(GH) treatment in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 1998; 83: 107-116.
12. Verhelst J, Abs R., Vanderweghe M et al. Two years of replacement therapy in adults with growth hormone deficiency. Clinical Endocrinology 1997; 47: 485-494.
13. Murray RD, Skillicorn CJ, Howell SJ, et al. Influences on quality of life in GH deficient adults and their effect on response to treatment. Clinical Endocrinology 1999; 51: 565-573.
14. McKenna SP, Doward LC, Alonso J et al. The QOL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Quality of Life Research 1999; 8: 373-383.
15. Murray RD, Skillicom CJ, Howell SJ et al. Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults. Clinical Endocrinology 1999; 50: 749-757.
16. Bengtsson BA, Abs R, Bennmarker H et al. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 1999; 84: 3929-3935.
17. Drake WM, Coyte D, Camacho-Hubner S et al. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. Journal of Clinical Endocrinology and Metabolism 1998; 83: 3913-3919.
18. McKenna SP, Vazquez JA, Pico A et al. Quality of life of adults in growth hormone deficiency in Spain and the effects of replacement therapy with growth hormone. Endocrinology and Metabolism 1997; 4 (Suppl. B): 168.
19. McKenna SP, Koppeschaar HPZ, Zelissen PMJ et al. The impact of replacement GH on the quality of life of patients: results of a clinical trial in the Netherlands. Endocrinology and Metabolism 1997; 4 (Suppl. B): 167.
20. Wessex Institute for Health Research and Development. Growth Hormone for growth hormone deficient adults. Development and Evaluation Committee (DEC) Report No 75. Bristol: South West Research and Development Directorate, 1997.
21. Brazier JE, Harper R, Jones NMB et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. British Medical Journal 1992; 305: 160-164.
22. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics 2002; 21: 271-92.
23. Drewett RF, Minns RJ, Sibly TF. Measuring outcome of total knee replacement using quality of life indices. Annals of the Royal College of Surgeons of England 1992; 74: 286-289.
24. Levin LA, Jonsson B. Cost-effectiveness of thrombolysis - a randomized study of intravenous rt-PA in suspected myocardial infarction. European Heart Journal 1992; 13: 2-8.
25. O'Brien B, Buxton M, Ferguson B. Measuring the effectiveness of heart transplant programmes: quality of life data and their relationship to survival analysis. Journal of Chronic Diseases 1987; 40: 37s-153s.